B+
Bull case
25%
Probability
Target price
$205.00
Analysis reference price unavailable
Analysis 2026-10-28 · RankAlpha Sentiment Codex
UHS
Universal Health ServicesBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$177.00
Analysis reference price unavailable
Analysis 2026-10-28 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$150.00
Analysis reference price unavailable
Analysis 2026-10-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-28
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+62.6
Score
AI commentary
Initial coverage reported an approximately 3% after-hours decline following the release, attributing concern to settlement costs and Medicaid-payment uncertainty; this is not a verified full-session reaction. Investing.com report Earnings-surprise framing differs by provider: Investing.com compared $5.22 adjusted EPS with $5.20 consensus, while Zacks reported a miss against $5.31. No verified post-print analyst revisions are incorporated. Social, options, short-interest and employee measures were unavailable; their zero values above are placeholders, not observations.
RankAlpha Sentiment Codex - 2026-10-28
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-28eventQ3 earnings: revenue growth, weaker profitMedium impact
UHS reported Q3 revenue of $4.733 billion, up 5.3%, but adjusted EPS fell to $5.22 from $5.69 and adjusted EBITDA net of noncontrolling interests fell 6.9%. Consensus comparisons conflict across providers, so the earnings surprise is not a clear bullish signal. [#SEC-8K-2026-10-27] UHS Q3 supplemental disclosures
2026-12-31eventLower-end 2026 EBITDA outlookMedium impact
UHS reaffirmed its July full-year ranges, including adjusted EBITDA net of noncontrolling interests of $2.610 billion–$2.717 billion and adjusted EPS of $22.28–$23.65, but now anticipates EBITDA toward the lower end. Subsequent results will test that narrower expectation. [#SEC-8K-2026-10-27] UHS Q3 supplemental disclosures
2027-01-26catalystSettlement and Medicaid-payment scrutinyMedium impact
Q3 included a $47 million favorable Medicaid supplemental-payment impact, partly offset by a $26 million increase in liability reserves primarily related to a tentative litigation settlement. Investors may scrutinize payment durability and residual legal exposure. [#SEC-8K-2026-10-27]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-28 • Updated nightlySource: Internal modelMethodology